These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 3018954)
1. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Sills T; Heptinstall S Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954 [TBL] [Abstract][Full Text] [Related]
2. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor. Hoet B; Arnout J; Deckmyn H; Vermylen J Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441 [TBL] [Abstract][Full Text] [Related]
4. Platelet behaviour in normal pregnancy, pregnancy complicated by essential hypertension and pregnancy-induced hypertension. Morrison R; Crawford J; MacPherson M; Heptinstall S Thromb Haemost; 1985 Oct; 54(3):607-11. PubMed ID: 3937260 [TBL] [Abstract][Full Text] [Related]
5. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. Liu FC; Liao CH; Chang YW; Liou JT; Day YJ Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675 [TBL] [Abstract][Full Text] [Related]
6. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative. Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809 [TBL] [Abstract][Full Text] [Related]
8. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
9. Aspirin and dazoxiben as inhibitors of platelet behaviour: modification of their effects by agents that alter cAMP production. Sills T; Cowley AJ; Heptinstall S Thromb Res; 1986 Apr; 42(1):91-8. PubMed ID: 3010495 [TBL] [Abstract][Full Text] [Related]
10. Thromboxane-mediated activation of platelets and enhancement of platelet uptake onto collagen-coated glass or deendothelialized rabbit aorta. Comparative effects of a thromboxane antagonist (EPO45) and a thromboxane synthetase inhibitor (dazoxiben). Menys VC; Davies JA Lab Invest; 1984 Feb; 50(2):184-9. PubMed ID: 6546403 [TBL] [Abstract][Full Text] [Related]
11. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets. Lam SC; Guccione MA; Packham MA; Mustard JF Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543 [TBL] [Abstract][Full Text] [Related]
12. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. Schumacher WA; Lucchesi BR J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881 [TBL] [Abstract][Full Text] [Related]
13. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour. Parry MJ Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997 [TBL] [Abstract][Full Text] [Related]
14. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. Jones EW; Cockbill SR; Cowley AJ; Hanley SP; Heptinstall S Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):39S-44S. PubMed ID: 6401999 [TBL] [Abstract][Full Text] [Related]
16. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606 [TBL] [Abstract][Full Text] [Related]
17. [Effects of imazodan and dazoxiben on cAMP levels and PGI2 production in cultured bovine aortic endothelial cells]. Jiang YY; Long K; Sheng ML Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):421-4. PubMed ID: 2559580 [TBL] [Abstract][Full Text] [Related]
18. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Manns JM; Brenna KJ; Colman RW; Sheth SB Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792 [TBL] [Abstract][Full Text] [Related]
19. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. Ashida S; Sakuma K Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259 [No Abstract] [Full Text] [Related]
20. The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals. Cowley AJ; Jones EW; Carter AJ; Hanley SP; Heptinstall S Br J Clin Pharmacol; 1985 Jan; 19(1):1-8. PubMed ID: 2983748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]